This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Asthma  • Allergy  • Infectious Diseases  • Viral Infections  • Neonatology and Infant Care  • Drug Therapy  • Alert me on articles by topic

Melony E. S. Sorbero, PhD, MS, MPH; Nahed O. ElHassan, MD, MPH; Caroline B. Hall, MD; Timothy P. Stevens, MD, MPH; Andrew W. Dick, PhD

Arch Pediatr Adolesc Med. 2007;161(5):520.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We welcome the opportunity to reply to Mahadevia and Malinoski's comments on our article, which correctly highlight the challenges of performing cost-effectiveness analyses (CEA) when complete data for components of the model are not available in the literature.

They state that our model¹ undervalues the benefit of avoiding asthma following respiratory syncytial virus (RSV) infection. First, as noted in our article,¹ a causal relationship between RSV infection and asthma has not been established. Second, factors that increase susceptibility to RSV infection likely also confer increased risk of asthma later. Incorporating future risk of asthma in a CEA model of RSV prophylaxis using palivizumab is novel and has not been included in prior CEA studies. Despite including future risk of asthma, which favors the . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis With Palivizumab
Parthiv J. Mahadevia and Frank J. Malinoski
Arch Pediatr Adolesc Med. 2007;161(5):519-520.
EXTRACT | FULL TEXT